Dashboard
Manage Tickers

BEAM Beam Therapeutics Inc.

Nasdaq beamtx.com


$ 30.85 $ 4.64 (17.86 %)    

Monday, 20-Oct-2025 19:48:28 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 612.11 $ 7.61 (1.26 %)
DIA $ 467.12 $ 5.24 (1.13 %)
SPY $ 671.75 $ 6.91 (1.04 %)
TLT $ 91.68 $ 0.35 (0.38 %)
GLD $ 401.36 $ 14.16 (3.64 %)
$ 30.62
$ 26.88
$ 30.55 x 201
$ 30.93 x 2
$ 26.82 - $ 30.80
$ 13.53 - $ 35.25
4,810,445
na
3.1B
$ 1.95
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 02-25-2025 12-31-2024 10-K
4 11-05-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 02-27-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-15-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-12-2020 06-30-2020 10-Q
22 05-12-2020 03-31-2020 10-Q
23 03-30-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ww-international-replimune-group-datavault-ai-grail-and-other-big-stocks-moving-higher-on-monday
WW International, Replimune Group, Datavau...
10/20/2025 14:13:22

hc-wainwright--co-reiterates-buy-on-beam-therapeutics-maintains-80-price-target
HC Wainwright & Co. Reiterates Buy on Beam...
10/10/2025 11:02:29

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 ...

jim-cramer-sees-more-upside-for-shopify-likes-coreweaves-ai-moves
Jim Cramer Sees More Upside For Shopify, L...
10/08/2025 12:33:52

Jim Cramer recommends buying Affirm Holdings (AFRM) on CNBC's Mad Money Lightning Round. Analysts also support Beam Therape...

is-beam-therapeutics-gaining-or-losing-market-support
Is Beam Therapeutics Gaining or Losing Mar...
09/22/2025 14:01:05

my-top-biotech-stock-picks-and-portfolio-strategy-for-the-next-3-10-years
My Top Biotech Stock Picks And Portfolio S...
09/18/2025 17:10:48

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of...

hc-wainwright--co-reiterates-buy-on-beam-therapeutics-maintains-80-price-target
HC Wainwright & Co. Reiterates Buy on Beam...
09/15/2025 11:41:37

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 ...

what-does-the-market-think-about-beam-therapeutics
What Does the Market Think About Beam Ther...
08/25/2025 14:01:00

pfizers-investigational-drug-flunks-late-stage-for-sickle-cell-disease
Pfizer's Investigational Drug Flunks Late-...
08/15/2025 19:35:43

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on ...

the-fda-grants-regenerative-medicine-advanced-therapy-designation-to-beam-therapeutics-beam-101-an-investigational-genetically-modified-cell-therapy-for-sickle-cell-disease
The FDA Grants Regenerative Medicine Advan...
08/14/2025 11:10:40

barclays-maintains-equal-weight-on-beam-therapeutics-lowers-price-target-to-21
Barclays Maintains Equal-Weight on Beam Th...
08/06/2025 14:06:18

Barclays analyst Gena Wang maintains Beam Therapeutics (NASDAQ:BEAM) with a Equal-Weight and lowers the price target from $2...

beam-therapeutics-q2-eps-100-beats-112-estimate-sales-847m-miss-1356m-estimate
Beam Therapeutics Q2 EPS $(1.00) Beats $(1...
08/05/2025 11:23:51

beam-therapeutics-enters-agreement-to-acquire-early-stage-life-sciences-company-for-403128-upfront-shares-and-up-to-89m-in-milestone-payments
Beam Therapeutics Enters Agreement To Acqu...
07/03/2025 20:37:40

On July 1, 2025, Beam Therapeutics Inc. (the "Company") entered into an Agreement and Plan of Merger pursuant to which ...

cathie-woods-ark-invest-continues-to-offload-coinbase-bets-big-on-sofi-technologies
Cathie Wood's Ark Invest Continues To Offl...
06/28/2025 02:48:14

Cathie Wood-led Ark Invest made notable trades on Friday, including selling shares in Coinbase and Roblox.

eli-lillys-13-billion-verve-deal-signals-confidence-in-gene-editing-space-analyst
Eli Lilly's $1.3 Billion Verve Deal Signal...
06/18/2025 17:59:21

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a...

beam-therapeutics-announces-new-data-from-beacon-phase-12-clinical-trial-of-beam-101-supporting-differentiated-profile-in-sickle-cell-disease-at-european-hematology-association-2025-congress-company-says-enrollment-complete-in-both-adult-and-adolescent-cohorts-of-beacon-trial-with-30-patients-expected-to-be-dosed-by-mid-2025
Beam Therapeutics Announces New Data From ...
06/13/2025 11:07:18

cathie-woods-ark-invest-continues-to-offload-palantir-loads-up-on-beam-therapeutics-gitlab
Cathie Wood's Ark Invest Continues To Offl...
06/12/2025 03:27:33

the-fda-has-granted-orphan-drug-designation-to-beam-therapeutics-beam-101-an-investigational-genetically-modified-cell-therapy-for-sickle-cell-disease
The FDA Has Granted Orphan Drug Designatio...
06/03/2025 11:03:50

Data from seven patients treated with BEAM-101 in the BEACON clinical trial were presented at the 66th American Society of Hema...

beam-therapeutics-receives-fda-orphan-drug-designation-for-beam-302-a-base-editing-therapy-targeting-alpha-1-antitrypsin-deficiency
Beam Therapeutics Receives FDA Orphan Drug...
05/29/2025 20:02:34

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, toda...

beam-therapeutics-to-present-new-data-from-beam-101-program-ii-sickle-cell-disease-at-european-hematology-association-2025-congress
Beam Therapeutics To Present New Data From...
05/14/2025 13:30:59

Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evalua...

beam-therapeutics-announces-us-fda-regenerative-medicine-advanced-therapy-designation-has-been-granted-to-beam-302-for-the-treatment-of-alpha-1-antitrypsin-deficiency
Beam Therapeutics Announces U.S. FDA Regen...
05/12/2025 20:33:51

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, toda...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION